Metformin improves cardiac stress tolerance and mitochondrial function during early aging Authors: Qun Chen, Jeremy Thompson, Ying Hu, Edward J Lesnefsky Published: 2026 ABSTRACT AbstractCardiac aging reduces stress resistance and increases the susceptibility to myocardial injury. Although cardiac dysfunction typically manifests in late-stage aging, the underlying process begins in middle age. Elevated endoplasmic reticulum (ER) stress is a key contributor to cardiac aging. We have shown that ER stress increases in middle-aged hearts and peaks in advanced age, while chronic metformin treatment reduces ER stress and improves mitochondrial function in late-aged hearts. This study examined whether metformin could protect early aged hearts exposed to a superimposed stress, given that ER stress is already elevated at this stage. Eighteen-month-old mice were used as a model of early cardiac aging, and isoproterenol (ISO; 100 mg/kg, subcutaneous injection injection for five consecutive days) was applied to induce cardiac stress. Metformin was administered in drinking water for two weeks prior to ISO treatment and continued throughout the exposure and recovery period. ISO treatment impaired cardiac function and mitochondrial respiration in 18-month-old mice compared to saline vehicle controls. Metformin reduced baseline ER stress and significantly improved both cardiac performance and mitochondrial function following ISO-induced stress. These findings demonstrate that chronic metformin treatment confers cardioprotection in early aging by attenuating ER stress and preserving mitochondrial function.Keywords: Aging, Endoplasmic reticulum, Endoplasmic reticulum stress, Isoproterenol, Cardiac injury Introduction Endoplasmic reticulum (ER) homeostasis is essential for cardiac myocyte function, supporting the synthesis of calcium-handling proteins, receptors, hormones, growth factors, and membrane proteins (Ren et al., 2021). Disruption of ER homeostasis, or ER stress, contributes to cardiac pathology through the activation of the unfolded protein response (UPR), which is implicated in cardiac hypertrophy and heart failure (Ren et al., 2021; Pu et al., 2025a; Zhang et al., 2025; Pu et al., 2025b; Wang et al., 2025a; Chang et al., 2024a; Yang et al., 2024; Wu et al., 2024). While ER stress initially functions to restore protein-folding homeostasis, prolonged or severe ER stress increases cell injury in pathological conditions including pressure overload, diabetes, and heart failure (Ren et al., 2021; Groenendyk et al., 2013; Chen et al., 2025; Preetha Rani et al., 2022; Wang et al., 2025b; Wang et al., 2024). We and others find that ER stress progressively increases during aging, especially in later-stage aging (Chen et al., 2020; Ye et al., 2021; Muthu et al., 2025). Mitochondria are closely connected with the ER through mitochondrial associated membranes, and it is not surprising to see that an increased ER stress is accompanied by dysfunctional mitochondria (Chen et al., 2024a; Chen et al., 2022; Chen et al., 2017; Chang et al., 2024b; Pang et al., 2024a; Pang et al., 2024b). An elevated ER stress occurs earlier than mitochondrial dysfunction during aging in the murine heart (Chen et al., 2020). In addition, the attenuation of ER stress in aged hearts leads to improved mitochondrial function (Chen et al., 2020; Chen et al., 2021; Shi et al., 2025). These results support that ER stress contributes to mitochondrial dysfunction during aging. Although cardiac mitochondrial dysfunction mainly occurs in late-stage aging, the aging process begins by middle age (Chen et al., 2020; Chen et al., 2021; Jones et al., 2015). ER stress begins to increase in middle aged murine hearts (18-month-old) and peaks in late-stage aging (24-month-old) (Chen et al., 2020). A hallmark of aging is reduced stress resistance and increased vulnerability to cardiac injury from superimposed heart disease (Lesnefsky et al., 1994; Lesnefsky et al., 1996). Currently, many studies focus on late-stage aging, and studies regarding stress responses earlier in the progression of aging are limited. Our previous study showed that ER stress is increased in 18-month-old mice (Chen et al., 2020). Compromised protein folding and calcium handling in myocytes due to increased ER stress may make 18-month-old mouse hearts more vulnerable to a superimposed stress. Isoproterenol (ISO) is a synthetic non-selective β-adrenergic agonist commonly used in animal models to induce cardiac hypertrophy and heart failure by increasing heart rate and cardiac workload, which leads to oxidative stress, mitochondrial dysfunction, and ER stress (Chen et al., 2025; Pan et al., 2022; Ashokkumar et al., 2018; Chang et al., 2025). Our previous study showed that ISO exposure led to increased ER stress and mitochondrial dysfunction in adult mice (Chen et al., 2025). ER stress occurs when misfolded or unfolded proteins accumulate inside the ER. Molecular chaperones of various classes contribute a critical role in maintaining ER homeostasis by removing misfolded protein aggregates. Molecular chaperones include heat shock proteins, calreticulin and calnexin, and oxidoreductases or protein disulfide isomerases (Meyer and Doroudgar, 2020). The chaperones have distinct functions in protein folding. Heat shock proteins including HSPA5 or GRP78 (BIP) bind to nascent proteins and prevent their misfolding and aggregation. Calnexin and calreticulin facilitate protein folding by binding to monoglycosylated protein moieties. Protein disulfide isomerase plays a critical role in protein folding and assembly through formation of disulfide bonds between cysteine residues (Meyer and Doroudgar, 2020). Calnexin is one of the ER lectins that interact with sarcoplasmic reticulum/ER Ca2+ ATPase (SERCA). Alteration of calnexin can lead to dysregulation of calcium homeostasis and participate in the development of heart failure (Preetha Rani et al., 2022). Angiotensin II stimulation leads to increased calnexin content and injury in cultured cells, whereas antioxidant treatment decreases cell injury by restoring calnexin levels to baseline (Ye et al., 2023). High fat and high fructose feeding increased cell injury with elevated calnexin content, and metformin treatment reduced the calnexin level and decreased cell injury (Preetha Rani et al., 2022). These studies suggest that upregulation of calnexin during stress conditions can augment cell injury. Transverse aortic restriction increases the calnexin content in rat hearts (Olgar et al., 2018). The induction of ER stress using thapsigargin also increased the calnexin level (Choi et al., 2024). Our previous study showed that ISO treatment increased the ER stress in mouse hearts (Chen et al., 2025). However, it is unclear if the ISO exposure leads to increased calnexin content. Activation of the UPR through three major signaling arms including PERK–eIF2α–ATF4–CHOP, IRE1 (Inositol-Requiring Enzyme 1), and ATF6 (Activating Transcription Factor 6) plays a key role in restoring homeostasis. Activation of these signaling pathways eventually leads to increased CHOP content (Ren et al., 2021). Elevation of CHOP is known to increase apoptosis by disrupting the balance between Bcl-2 and bax/Bim (Fang et al., 2021). Activation of CHOP can also increase oxidative stress by impairing mitochondrial function (Fu et al., 2010). Our previous studies found that chronic metformin treatment reduced ER stress and mitochondrial dysfunction in aged hearts in the baseline condition, as indicated by decreased CHOP content (Chen et al., 2021). The current study addressed the potential contribution of chronic metformin treatment to potentially decrease ER stress and protect downstream mitochondrial function in early aged hearts under an exogenous stress condition. Results from our study will provide guidance to support the translational use of metformin treatment to protect aged hearts during the basal condition and to potentially decrease cardiac injury and dysfunction during the stress of subsequent cardiac disease. Materials and methods Induction of heart failure in C57BL/6 mice using isoproterenol (ISO) Adult (3-month-old) and early-aging (18-month-old) C57BL/6 male mice were obtained from the National Institute on Aging (NIA). Isoproterenol (ISO, 100 mg/kg) was administered subcutaneously once daily for 5 consecutive days, as described in previous work (Chen et al., 2025; Pan et al., 2022). ISO was prepared in saline, and saline alone served as the vehicle control (Chen et al., 2025; Pan et al., 2022). For metformin treatment, mice received metformin (320 mg/kg body weight) dissolved in drinking water containing sucrose (0.2 g/100 ml) as a sweetener for 2 weeks (Chen et al., 2021), followed by an additional 4 weeks of treatment following ISO exposure, while metformin or vehicle administration was continued. The chosen metformin dose was based on our prior studies in elderly mice (Chen et al., 2021). Control animals received sucrose-containing water (0.2 g/100 ml) as a vehicle for the same duration prior to ISO administration (Chen et al., 2021). At the end of the treatment protocol, mice were deeply anesthetized with pentobarbital sodium (100 mg/kg, i.p.), and hearts were collected for mitochondrial isolation four weeks after the final saline or ISO injection (Fig. 1A). Panel A shows the experimental protocol. Baseline cardiac function was measured by echocardiography (ECHO) before vehicle or ISO treatment. Cardiac function was then monitored weekly after ISO or saline exposure. Panels B and C show that five consecutive days of ISO treatment led to decreased ejection fraction (EF) and fractional shortening (FS) in 18-month-old mice during the second, third, and fourth weeks after ISO exposure, compared to saline-treated controls, indicating that ISO treatment impaired cardiac function in 18-month-old mice. These results demonstrate that five consecutive days of ISO exposure are sufficient to induce cardiac dysfunction in early-aged mice. Data are presented as mean ± SEM, *p < 0.05 vs. saline vehicle treatment. N = 10 in each group. Isolation of cytosol and mitochondria from a single mouse heart Heart mitochondria were isolated as previously described (Chen et al., 2024b). Briefly, harvested mouse hearts were blotted dry, weighed, and minced in ice-cold buffer A (in mM: 100 KCl, 50 MOPS [3-(N-morpholino)propanesulfonic acid], 1 EGTA, 5 MgSO4, and 1 ATP). The minced tissue was homogenized with a polytron tissue homogenizer at 10,000 rpm for 2.5 s in the presence of trypsin (5 mg/g tissue), which was used to enhance mitochondrial yield and reduce cytosolic contamination. The homogenate was incubated with trypsin for 15 min at 4 °C, then diluted with an equal volume of buffer B [buffer A supplemented with 0.2% bovine serum albumin (BSA)]. The mixture was centrifuged at 500 ×g for 10 min, and the resulting supernatant was centrifuged at 3000 ×g for 10 min to pellet mitochondria. The pellet was washed once with KME buffer (100 mM KCl, 50 mM MOPS, 0.5 mM EGTA) and centrifuged again at 3000 ×g for 10 min to obtain the final mitochondrial fraction. Mitochondria were resuspended in KME buffer for subsequent functional studies (Chen et al., 2024b). Mitochondrial oxidative phosphorylation Mitochondrial oxygen consumption was measured at 30 °C using a Clark-type oxygen electrode, as previously described (Chen et al., 2024b). Mitochondria were incubated in oxidative phosphorylation buffer (in mM: 80 KCl, 50 MOPS, 1 EGTA, 5 KH2PO4, and 1 mg/ml defatted, dialyzed bovine serum albumin, pH 7.4). Glutamate (20 mM) plus malate (10 mM) or pyruvate (20 mM) plus malate (10 mM) were used as substrates for complex I. Succinate (20 mM) with rotenone (7.5 μM) was used for complex II, and TMPD (N,N,N′,N′-Tetramethyl-p-phenylenediamine, 1 mM) –ascorbate (10 mM) with rotenone (7.5 μM) served as the complex IV substrate (Chen et al., 2025; Chen et al., 2024b). Determination of calcium retention capacity (CRC) in isolated mitochondria Calcium retention capacity (CRC) was used to evaluate the sensitivity of isolated mitochondria to calcium-induced mitochondrial permeability transition pore (MPTP) opening (Chen et al., 2012). Isolated mitochondria (250 μg/ml) were incubated in a medium containing 150 mM sucrose, 50 mM KCl, 2 mM KH2PO4, and 5 mM succinate in 20 mM Tris/HCl, pH 7.4. Calcium (5 nmol per pulse) was added sequentially to induce MPTP opening. Extra-mitochondrial Ca2+ levels were monitored using 0.5 μM Calcium Green-5N, with fluorescence recorded at excitation and emission wavelengths of 500 and 530 nm, respectively (Chen et al., 2012). Immunoblotting Cytosolic and mitochondrial samples were mixed with sample buffer and denatured at 95 °C for 5 min. Proteins were separated on 12% or 4–15% Tris–glycine gels (Bio-Rad, Hercules, CA) and transferred onto PVDF membranes using a semi-dry transfer system (Bio-Rad). Membranes were blocked for 1 h at room temperature in 5% (w/v) non-fat dry milk in TBST (10 mM Tris, pH 7.5; 150 mM NaCl; 0.1% Tween-20). After a 5-minute wash in TBST, membranes were incubated overnight at 4 °C with the indicated primary antibodies (see Table 1). Following washes in TBST, membranes were incubated for 1 h at room temperature with HRP-conjugated secondary antibodies (anti-mouse or anti-rabbit IgG F (ab′)2, 1:10,000; GE Healthcare Life Sciences, Piscataway, NJ). Signal detection was performed using ECL Plus Western Blotting Detection Reagents (GE Healthcare Life Sciences). Blots were digitally analyzed using Image Lab 6.0 software (Bio-Rad) (Chen et al., 2024a). Table 1Antibodies used in the current study.Antibody nameCompanyCatalog numberConcentrationATF6Santa Cruzsc1666591:100P-AMPKCell Signaling25311:500CHOPCell Signaling28951:500CalnexinCell Signaling26791:1000Cytochrome cBD Biosciences556,4331:3000 Antibodies used in the current study. Measurement of cardiac function using echocardiography Echocardiography and Doppler imaging were performed using the Vevo770™ system (VisualSonics Inc., Toronto, Canada) as previously described (Chen et al., 2022). Mice were anesthetized with isoflurane and positioned supine. Cardiac function was assessed at baseline and weekly after ISO administration. The thoracic area was carefully shaved, and ultrasound gel applied to ensure optimal imaging. Statistical analyses Data are presented as mean ± standard error (SEM). For comparisons involving three or more groups, one-way ANOVA was used when the data passed normality and equal variance tests. When the ANOVA yielded a significant F value, pairwise comparisons were performed using the Student–Newman–Keuls test. Comparisons between two groups were conducted using an unpaired Student's t-test (SigmaStat 3.5, Systat, Richmond, CA). A p-value of <0.05 was considered significant. Results Isoproterenol (ISO) exposure impaired cardiac function in 18-month mice Our previous study showed that ISO exposure (daily injections for five consecutive days) impairs cardiac contractility in 3-month-old C57BL/6 mice (Chen et al., 2025). The same method was used to determine whether ISO exposure induces cardiac dysfunction in 18-month-old male mice. The experimental protocol is shown in Fig. 1A. Baseline cardiac function was first assessed by echocardiography (ECHO) prior to saline or ISO treatment. Cardiac function was then monitored weekly following ISO or saline treatment. Mice were euthanized in the fourth week after treatment, and their hearts were collected for mitochondrial isolation. ISO exposure led to decreased EF (Fig. 1B) and FS (Fig. 1C) in 18-month-old mice during the second, third, and fourth weeks after treatment compared to saline-treated controls, indicating decreased cardiac contractility. Saline or ISO treatment did not alter body weight in either group (Table 2). These results demonstrate that five consecutive days of ISO exposure are sufficient to induce cardiac dysfunction in early-aged mice. Table 2Body weight (g) in 18-month-old mice with or without Isoproterenol (ISO) exposure and metformin treatment.GroupsPre-feedingPre-treatment1 W post treatment2 W post treatment3 W post treatment4 W post treatmentSaline (n = 10)32.9 ± 0.731.9 ± 0.732.0 ± 0.732.2 ± 0.632.7 ± 0.6ISO (n = 10)32.7 ± 0.431.6 ± 0.431.4 ± 0.431.8 ± 0.432.3 ± 0.5Sucrose +ISO (n = 8)34.4 ± 0.533.0 ± 0.532.1 ± 0.432.2 ± 0.431.6 ± 0.431.5 ± 0.3Metformin +ISO (n = 10)32.9 ± 0.831.8 ± 0.831.1 ± 0.531.0 ± 0.730.8 ± 0.630.9 ± 0.7Mean ± SEM, p = NS. There were no significant alterations in body weight in mice receiving saline, ISO, sucrose+ ISO, or metformin + ISO treatment. (W-week). Body weight (g) in 18-month-old mice with or without Isoproterenol (ISO) exposure and metformin treatment. Mean ± SEM, p = NS. There were no significant alterations in body weight in mice receiving saline, ISO, sucrose+ ISO, or metformin + ISO treatment. (W-week). Chronic metformin feeding protected cardiac function in ISO-treated 18 months mice Two weeks of metformin feeding improved mitochondrial function in later stage elderly (24-month-old mice) in the baseline condition (Chen et al., 2021). We investigated whether chronic metformin feeding can protect cardiac contractile function in 18-month-old mice following ISO-induced stress. Baseline cardiac function was measured by ECHO before sucrose or metformin feeding. Sucrose was used as a sweetener to mask the odor of metformin (Chen et al., 2017; Chen et al., 2021). Two weeks of sucrose feeding did not alter EF (%) [Mean ± SEM, 72.4 ± 2.3 (before feeding) vs. 72.5 ± 4.1 (after two weeks of feeding), p = NS] or FS (%) [Mean ± SEM, 40.9 ± 2.1 (before feeding) vs. 41.4 ± 3.5 (after two weeks of feeding), p = NS] in 18-month-old mice. Two weeks of metformin feeding also did not alter EF (%) [Mean ± SEM, 73.6 ± 1.6 (before feeding) vs. 73.5 ± 3.6 (after two weeks of feeding), p = NS] or FS (%) [Mean ± SEM, 44.4 ± 2.0 (before feeding) vs. 42.0 ± 2.6 (after two weeks of feeding), p = NS] in 18-month-old mice. Two weeks of sucrose or metformin feeding did not alter body weight in either group (Table 2). These results indicate that two weeks of sucrose or metformin feeding does not alter cardiac function in 18-month-old mice in the basal condition. Fig. 2A shows the experimental protocol used in this study. Cardiac function was measured again after two weeks of sucrose or metformin feeding and was used as the pre-treatment baseline. All mice then underwent ISO exposure for five consecutive days. Mice continued to receive metformin or sucrose throughout ISO exposure, and the total feeding period was six weeks. Cardiac function was monitored weekly after ISO exposure. Mice were euthanized in the fourth week following ISO exposure, and their hearts were collected for mitochondrial isolation. ISO exposure led to decreased EF (Fig. 2B) and FS (Fig. 2C) in 18-month-old mice receiving sucrose during the second, third, and fourth weeks after ISO exposure, indicating that sucrose feeding does not alter ISO-induced cardiac dysfunction in these mice. In contrast, ISO exposure did not decrease EF (Fig. 2B) or FS (Fig. 2C) in 18-month-old mice receiving metformin for the two weeks before and during the four weeks following ISO exposure. These results suggest that chronic metformin feeding preserves cardiac contractile function in early-aged mice during the superimposed stress condition of ISO exposure. Panel A shows the experimental protocol. Baseline cardiac function was measured by echocardiography before sucrose or metformin (MET) feeding. Mice were fed sucrose or MET for 6 weeks, with cardiac function reassessed after 2 weeks as the pre-ISO baseline. All mice then received ISO for 5 consecutive days, and cardiac function was monitored weekly thereafter. Panels B and C show that ISO decreased ejection fraction (EF) and fractional shortening (FS) in 18-month-old sucrose-fed mice during weeks 2–4 after ISO, whereas MET-fed mice were protected from these changes. These results indicate that chronic metformin feeding preserves cardiac function in 18-month-old mice following ISO stress. Data are presented as mean ± SEM; †p < 0.05 vs. ISO + sucrose-fed mice. n = 8 in the sucrose + ISO group and n = 10 in the metformin + ISO group. ISO exposure led to decreased oxidation through cytochrome oxidase Our previous study showed that ISO exposure impairs mitochondrial function in young adult C57BL/6 mice, as demonstrated by decreased oxidation through cytochrome oxidase (complex IV) (Chen et al., 2025). Mitochondria were isolated from mice in the fourth week following ISO exposure. There were no significant differences in the rate of oxidative phosphorylation between saline- and ISO-exposed 18-month-old mice when glutamate + malate was used as a complex I substrate (Table 2). However, ADP-stimulated respiration was decreased in ISO-exposed mice compared to saline when succinate was used as a complex II substrate (Table 2). ISO exposure also led to decreased oxidation through cytochrome oxidase compared to saline vehicle (Fig. 3A), indicating that ISO stress impairs cytochrome oxidase function in 18-month-old mice, consistent with previous observations in adult mice (Chen et al., 2025). Panel A shows that 5 days of ISO exposure decreased respiration through cytochrome oxidase in 18-month-old mice, which was improved by metformin but not sucrose feeding, indicating protection against ISO-induced mitochondrial dysfunction. Panel B shows that ISO reduced calcium retention capacity (CRC), supporting increased susceptibility to MPTP opening, which was prevented by metformin. Panels C and D show that ISO increased cytosolic cytochrome c, indicating mitochondrial release, whereas metformin reduced this effect, consistent with decreased MPTP opening in situ. Data are presented as mean ± SEM, *p < 0.05 vs. saline; †p < 0.05 vs. ISO + sucrose fed mice. Due to the limited number of wells available on a single gel, not every sample was used for immunoblotting. Metformin treatment improved oxidative phosphorylation in ISO-exposed mice As expected, the rates of oxidative phosphorylation were not altered in ISO-exposed mice receiving metformin or sucrose feeding when glutamate + malate or succinate were used as complex I or complex II substrates, respectively (Table 3). However, metformin feeding improved oxidation through cytochrome oxidase compared to sucrose in 18-month-old mice following ISO exposure (Fig. 3A). These results support that chronic metformin feeding reduces cytochrome oxidase injury following ISO-induced cardiac stress. Table 3The rate of oxidative phosphorylation in mouse heart mitochondria from 18-month-old mice with or without Isoproterenol (ISO) exposure and metformin treatment.GroupsSaline(n = 10)ISO(n = 10)Sucrose + ISO(n = 8)Metformin + ISO(n = 10)Complex I substrates: glutamate + malateState 3 (nAO/min/mg)257 ± 9247 ± 6240 ± 8262 ± 14State 4 (nAO/min/mg)62 ± 453 ± 953 ± 252 ± 4RCR4.3 ± 0.34.8 ± 0.24.9 ± 0.45.4 ± 0.52 mM ADP (nAO/min/mg)301 ± 13275 ± 8266 ± 15299 ± 17Complex II substrates: Succinate + rotenoneState 3 (nAO/min/mg)792 ± 9666 ± 14*757 ± 12789 ± 9State 4 (nAO/min/mg)225 ± 6201 ± 4228 ± 4229 ± 5RCR3.5 ± 0.13.3 ± 0.13.3 ± 0.13.5 ± 0.12 mM ADP (nAO/min/mg)770 ± 14681 ± 15*785 ± 11784 ± 9Mean ± SEM.*p = 0.001 vs. saline for state 3 comparison.*p = 0.002 vs. saline for 2 mM ADP comparison. The rate of oxidative phosphorylation in mouse heart mitochondria from 18-month-old mice with or without Isoproterenol (ISO) exposure and metformin treatment. Mean ± SEM. p = 0.001 vs. saline for state 3 comparison. p = 0.002 vs. saline for 2 mM ADP comparison. Metformin decreased the ISO-induced susceptibility to MPTP opening A decrease in calcium retention capacity (CRC) reflects an increased sensitivity to MPTP opening in isolated heart mitochondria (Chen et al., 2012). ISO exposure significantly decreased CRC compared to saline (Fig. 3B), supporting that ISO exposure sensitizes mitochondria to MPTP opening in 18-month-old mice. Metformin, but not sucrose feeding, improved the CRC in ISO-exposed mice (Fig. 3B), indicating that chronic metformin feeding decreases the susceptibility to MPTP opening in 18-month-old mice exposed to ISO. Increased MPTP opening promotes the release of cytochrome c from mitochondria into the cytosol, so an elevated cytosolic cytochrome c content is an indicator of in situ MPTP opening. Cytosolic cytochrome c content was increased in ISO-exposed mice compared to saline controls (Fig. 3C), consistent with enhanced MPTP opening. In contrast, metformin treatment decreased the cytosolic cytochrome c content in ISO-exposed mice compared to sucrose (Fig. 3D). These results further support that metformin reduces the in situ probability of MPTP opening in ISO-stressed 18-month-old mice. Metformin increased AMPK phosphorylation in ISO exposed 18-month-old mice We tested whether metformin can still activate AMPK in mice exposed to ISO. ISO exposure alone did not increase phospho-AMPK levels compared to saline (Fig. 4A), indicating that ISO alone does not lead to the activation of AMPK in 18-month-old mice. However, phospho-AMPK levels were increased in mice receiving metformin during ISO exposure compared to sucrose-fed controls (Fig. 4B), demonstrating that chronic metformin treatment can still activate AMPK in 18-month-old mice under ISO-induced stress. Panel A shows that there was no significant difference in phospho-AMPK levels between saline and ISO exposure, suggesting that ISO exposure alone does not alter AMPK phosphorylation status. Panel B shows that metformin feeding increased AMPK phosphorylation compared to sucrose-fed mice, indicating that metformin enhances AMPK phosphorylation during ISO exposure. Data are presented as mean ± SEM, †p < 0.05 vs. ISO + sucrose-fed mice. Due to the limited number of wells available on a single gel, not every sample was used for immunoblotting. Metformin decreased the ER stress in ISO-exposed 18-month-old mice Increased contents of CHOP and cleaved ATF6 indicate elevated ER stress (Chen et al., 2020). The contents of CHOP (Fig. 5A) and cleaved ATF6 (Fig. 5C) were significantly elevated in ISO-exposed 18-month-old mice compared to saline, indicating that ISO exposure further augments ER stress in these mice. Metformin treatment reduced CHOP (Fig. 5B) and cleaved ATF6 (Fig. 5D) contents in ISO-exposed mice compared to sucrose-fed controls, indicating that chronic metformin feeding decreases ER stress in 18-month-old mice despite ISO exposure. ER stress also increases the calnexin content, which contributes a key role in calcium homeostasis (Choi et al., 2024). Calnexin content was increased in ISO-exposed 18-month-old mice compared to saline (Fig. 5E), whereas metformin treatment reduced calnexin content in ISO-exposed mice compared to sucrose-fed controls (Fig. 5F). These results suggest that chronic metformin feeding might improve calcium homeostasis by modulating calnexin in 18-month-old mice. Panel A shows that ISO exposure increased CHOP content compared to saline, whereas metformin feeding reduced CHOP levels in ISO-exposed hearts (Panel B). Panel C shows that ISO exposure increased ATF6 cleavage compared to saline, while metformin feeding attenuated ATF6 cleavage in ISO-exposed hearts (Panel D). Panel E shows that ISO exposure increased calnexin content compared to saline, consistent with possible disruption in calcium homeostasis. Panel F shows that metformin feeding reduced calnexin content in ISO-exposed hearts, indicating a potential for improved calcium homeostasis following ISO exposure, potentially related to the decrease in ER stress shown in Panels B and D. Data are presented as mean ± SEM, *p < 0.05 vs. saline; †p < 0.05 vs. ISO + sucrose-fed mice. Due to the limited number of wells available on a single gel, not every sample was used for immunoblotting. Discussion The novel findings of the current study show that isoproterenol (ISO) induced cardiac stress leading to contractile dysfunction further increased ER stress in early aging mice, and that chronic metformin feeding is still able to reduce ER stress in these early aging mice despite ISO exposure. Furthermore, we identified that metformin feeding preserves mitochondrial function in ISO-treated early-aged mice. In addition, ISO exposure elevates calnexin levels, which may facilitate the development of heart failure by disrupting calcium communication between the ER and mitochondria. Metformin treatment decreased calnexin levels in ISO-exposed hearts. Taken together, the reduction of ER stress and the preservation of mitochondrial function play key roles in metformin-mediated protection in early-aged hearts following ISO treatment. ISO stimulation increases heart rate, contractility, and myocardial oxygen demand. Accordingly, ISO is commonly used to mimic sympathetic overstimulation and to induce contractile dysfunction and heart failure in rodents (Chen et al., 2025; Pan et al., 2022). We and others have shown that five consecutive days of ISO exposure impairs cardiac contractile function in adult mice (Chen et al., 2025; Pan et al., 2022). In the present study, we found that ISO exposure decreased contractility in early-aged mice. Additionally, ISO exposure impaired mitochondrial function in these mice. There was a decrease in respiration through cytochrome oxidase in the terminal portion of the electron transport chain, likely due to the loss of cytochrome c from mitochondria. Furthermore, the susceptibility to undergo mitochondrial permeability transition pore (MPTP) opening was increased by ISO-induced stress, with the release of cytochrome c from mitochondria to cytosol supporting an increased prevalence of MPTP opening in situ following ISO exposure. Chronic metformin treatment improved both cardiac and mitochondrial function in these early-aged hearts. We also observed that ISO exposure increased ER stress in the early-aged hearts, whereas ER stress was decreased in early-aged hearts receiving metformin. These results suggest that chronic metformin treatment may be a promising strategy to protect early aged hearts from the cardiac stress of superimposed cardiac disease. ER stress plays a key role in ISO-induced cardiac dysfunction (Chen et al., 2025). Our previous study found that chronic metformin treatment decreased the ER stress present at baseline in aged murine hearts at the later aging stage of 24-month-old as shown by decreased CHOP and ATF 6 contents (Chen et al., 2021). Here we show that chronic metformin treatment decreases the ER stress in ISO-exposed 18-month-old early aging mice. These results support that the increased ER stress contributes a critical role in ISO-induced cardiac dysfunction. Furthermore, not only does metformin treatment reduce the surge of ER stress of late-stage aging that leads to mitochondrial dysfunction (Chen et al., 2021), but it also mitigates the disease-associated increase in ER stress leading to mitochondrial dysfunction in the current study. Our previous study showed that one week of ISO exposure impairs mitochondrial function in adult mice, with the primary deficit being decreased respiration through cytochrome oxidase due to the loss of cytochrome c from mitochondria (Chen et al., 2025). In the present study, we found that ISO exposure did not alter respiration with complex I substrates. However, it led to decreased oxidation with complex II substrates most likely due to a decrease in respiration through cytochrome oxidase (Table 3). These results highlight that the defect is in the distal electron transport chain and is consistent with our previous findings that ISO stimulation primarily reduces respiration through cytochrome oxidase (Chen et al., 2025). In the current study, ISO stimulation also significantly increased cytosolic cytochrome c content in 18-month-old mice, indicating a loss of cytochrome c from the mitochondria in ISO-treated subjects. Cytochrome c is normally located in the mitochondrial intermembrane space and is released into the cytosol when outer mitochondrial membrane permeability increases (Chen et al., 2006). Consistent with this loss, we observed that susceptibility to MPTP opening was increased in ISO-exposed hearts. Chronic metformin treatment reduced the susceptibility to MPTP opening in isolated mitochondria and subsequent cytochrome c release in situ in ISO-exposed early-aged mice, supporting that the protective effect of metformin is likely mediated by a reduced susceptibility to MPTP opening. We and others have shown that induction of acute ER stress sensitizes mitochondria to MPTP opening in adult mice (Chen et al., 2024a; Chen et al., 2022; Mohsin et al., 2020). We also found that increased ER stress contributes to enhanced MPTP opening in aged hearts. One consequence of ER stress is disruption of intracellular calcium homeostasis, which activates calcium-dependent proteases, including calpains. Calpain activation further promotes MPTP opening during ER stress. ER stress is elevated in adult hearts following ISO treatment (Chen et al., 2024a; Chen et al., 2022). In the present study, we found that ISO treatment increased ER stress in early-aged hearts. Chronic metformin treatment reduced ER stress in these hearts, accompanied by decreased MPTP opening, suggesting that ER stress reduction plays a key role in metformin-mediated inhibition of MPTP. In addition to attenuating ER stress, metformin treatment can also reduce MPTP opening by activating cellular signaling pathways (Chen et al., 2024c). Metformin is a well-known AMPK activator. Our previous work showed that AMPK activation decreases MPTP opening in aged hearts through phosphorylation of AKT and GSK-3β, which inhibits GSK-3β and reduces MPTP opening (Chen et al., 2024c). In the present study, we found that chronic metformin treatment increased AMPK phosphorylation in early-aged hearts. Thus, activation of AMPK signaling may also contribute to decreased MPTP opening in ISO-treated early-aged mice receiving metformin. Our study has several limitations. For instance, while we observed that metformin feeding decreased calnexin content in 18-month-old mice as a potential benefit, the mechanism of the decrease will require additional future study, including the study of potential alteration of gene expression. Additionally, although our previous work demonstrated that metformin activates AMPK and downregulates mTOR in 24-month-old mice (Chen et al., 2021), a selective AMPK inhibitor is required to confirm the specific role of AMPK-mediated protection in the 18-month-old cohort (Liu et al., 2014). The present study shows that ISO exposure impairs mitochondrial function in early-aged mice by increasing ER stress, whereas chronic metformin treatment protects mitochondrial function in early-aged mice by reducing ER stress. These results underscore the clinical relevance of targeting ER stress pathways to preserve mitochondrial function and improve cardiac resilience in patients at risk for age-related cardiovascular disease. In addition to reducing ER stress, metformin exerts multiple other potentially protective cardiometabolic effects, including activation of AMPK (Chen et al., 2021; Tian et al., 2021), attenuation of MPTP opening (Jiang et al., 2020), enhancement of fatty acid oxidation (You et al., 2004), and reduction of oxidative stress (Rösen and Wiernsperger, 2006). Chronic metformin therapy has translational relevance (Dokras et al., 2025), including in a current clinical trial to improve clinical outcomes in non-diabetic patients in the Department of Veterans Affairs funded IMPACT trial. Thus, following further investigation, chronic metformin therapy could be used to reduce the clinical impact of superimposed cardiac disease in the high-risk elderly patient. Acknowledgments This work was supported by the Office of Research and Development, Medical Research Service Merit Review Award (2IO1BX001355-01A2), Department of Veterans Affairs (QC, JT, YH, EJL), the National Institute on Aging (1R21AG054975-01 and 4R33AG071249-03) (QC, EJL), Pauley Heart Center Grant (QC) and the Pauley Heart Center, Virginia Commonwealth University (QC, EJL). Footnotes CRediT authorship contribution statement Qun Chen: Writing – original draft, Supervision, Methodology, Conceptualization. Jeremy Thompson: Methodology, Formal analysis, Data curation. Ying Hu: Methodology, Data curation. Edward J. Lesnefsky: Writing – review & editing, Funding acquisition, Conceptualization. Declaration of competing interest All authors have read the journal's policy on authorship agreement and disclosure of potential conflicts of interest and have none to declare. The authors have read the journal's authorship agreement, and the manuscript has been reviewed and approved by all named authors. Data availability Data will be made available on request. References Associated Data Data Availability Statement Data will be made available on request.